


Applying Evidence Analysis to the Creation of Evidence Based Guideline and Toolkits



Steps in the Evidence Analysis Process





What are Evidence-Based Nutrition Practice Guidelines?





Evidence Summaries & Conclusion Statements = what the evidence says

Guideline = course of action for the practitioner based on the evidence State "what to do" and "why" for the RD

Academy of

and Dietetics

- Rated based on benefits vs. harms and grade of supporting evidence
- Linked to supporting analyzed evidence
- Provide treatment algorithms



Features of Guidelines

- Executive Summary of Recommendations: list only of recommendations, no supporting evidence
- Introduction: scope, intent, methods, benefits/harms
- **Recommendations:** a series of guiding statements that propose a *course of action* for practitioners
- Algorithms: step-by-step flowchart for treatment of the specific disease/condition

Executive Summary of Recommendations EVIDENCE ANALYSIS LIBRARY®



Major Recommendations		
Algorithms		
CELIAC DISEASE NUTRITION ASSESSMENT		
CELIAC DISEASE NUTRITION DIAGNOSIS		
CELIAC DISEASE NUTRITION INTERVENTION		
CELIAC DISEASE NUTRITION MONITORING AND EVALUATION		
Executive Summary		
Executive Summary Introduction		
Introduction		
Introduction SCOPE OF GUIDELINE		
Introduction SCOPE OF GUIDELINE STATEMENT OF INTENT		

EXECUTIVE SUMMARY

Executive Summary of Recommendations

Below are the major recommendations and ratings for the Academy of Nutrition and Dietetics Celiac Disease (CD) Evidence-Based Nutrition Practice Guideline. Click here to view the Guideline Overview. More detail (including the evidence analysis supporting these recommendations) is available on this website to Academy members and EAL subscribers under Major Recommendations.

To see a description of the Academy Recommendation Rating Scheme (Strong, Fair, Weak, Consensus, Insufficient Evidence), click here.

The CD Recommendations are listed below. [Note: If you mouse-over underlined acronyms and terms, a definition will pop up.]

Free on EAL

Published on National Guidelines Clearinghouse

eat[®] Academy of

d Diatatica

Executive Summary of Recommendations

right. Academy of Nutrition and Dietetics

Strong

Imperative

CIU: Patient Positioning

The Registered Dietitian (RD) should recommend that critically ill adult patients be positioned in a 30 to 45 degree head of bed elevation, if not contraindicated. Research shows that this practice decreases the incidence of aspiration pneumonia and reflux of gastric contents into the esophagus and pharynx.

Strong Imperative

CIU: Gastric Residual Volume

When gastric residual volumes (GRVs) are used as one of the indicators for tolerance, the Registered Dietitian (RD) should recommend against holding enteral nutrition (EN) when GRV is less than 500ml in the absence of signs of intolerance (e.g., abdominal distention, nausea, vomiting) in critically ill adult patients. Research indicates that holding EN when GRV is less than 500ml is associated with delivery of less EN. GRV does not correlate with risk for aspiration.

Fair

Conditional

CIU: Use of a Promotility Agent

If the critically ill adult patient has gastroparesis or gastric residual volumes (GRVs) ranging from 200 to 500ml and there are no contraindications, then the Registered Dietitian (RD) should recommend the use of promotility agents. Research indicates that the use of a promotility agent has been associated with increased gastric emptying, improved enteral nutrition (EN) delivery and possibly reduced risk of aspiration.

Strong Conditional

CIU: Enteral Formulas Containing Immune-Modulating Nutrients in Patients Without ARDS or Acute Lung Injury

For intensive care unit (ICU) patients without acute respiratory distress syndrome (ARDS), acute lung injury or severe sepsis, the Registered Dietitian (RD) should carefully evaluate using immune-modulating enteral formulas containing some combination of arginine, glutamine, nucleotides, antioxidants and fish oil. Some primary studies and metaanalyses with mixed populations have shown benefits in reducing infectious complications and hospital length of stay (LOS). Research is inconclusive regarding reducing cost of medical care, days on mechanical ventilation, or mortality for mixed ICU patients, including surgical and trauma patients. Research on patients with <u>ARDS</u> or acute lung injury was not included in this analysis. Recommendation Rating Label (conditional or imperative)

Major Recommendations

eger Academy of Nutrition right and Dietetics EVIDENCE ANALYSIS LIBRARY®							
> Projects	Methodology	Resources	Index	About	Site Search	٩	
					. 등 🗗 A'	A'	
eliac Disease							
IAJOR RECOMM	ENDATIONS						
ecommendations							
	tegorized in terms of either condit he target population and do not ir			tements clearly define a s	pecific situation, imperative st	tatements	
onditional recommendat	ions are presented in an if/then fo	ormat, such that:					
If CONDITION the	n ACTION(S) because REASON	(S)					
	triggers one or more guideline-s text that would limit their applicat			ations include terms such a	as "require, " "must, " and "sho	ould, " and	
esources Available with	Each Recommendation						
addition to the recomm	endation statement and strength i	ating, you will find on each	recommendation page:				
 A statement of jus Detailed information precommendation precommendatin precommendation precommendatin precommendation precommendatio	ummary of the evidence analyzed iffication, or reason for the streng on on the evidence supporting the vage) the end of each recommendation ummary of the article analyzed in	th of the recommendation recommendations and bac page that includes all the s	kground narrative (availa				
elow, you will find a list on erecommendation title.	f the Celiac Disease Recommend	dations organized by the ste	eps in ADA's Nutrition Ca	re Process. To see the Re	commendation Summary, jus	st click on	
eliac Disease (CD) Maj	or Recommendations						
D: Medical Nutrition The	гару						
utrition Assessment							
D: Assessment of Food	Nutrition-Related History						
							1

CIU: Supplemental Intravenous Glutamine

If a <u>critically ill adult</u> patient is receiving <u>parenteral nutrition</u> (PN), the Registered Dietitian (RD) should consider use of supplemental intravenous (IV) glutamine to reduce infectious complications. Research indicates that glutamine-supplemented <u>PN</u> reduced infectious complications in adult critically ill patients in four of five positive quality <u>randomized controlled trials</u> (RCTs). However, research shows that glutamine-supplemented PN does not reduce hospital length of stay (LOS) and there is no association between glutamine-supplementated PN and reduced cost of medical care, days on mechanical ventilation or mortality.

Rating: Strong Conditional	Recommendation Page: -Recommendation -Risks/Harms
	-Conditions of Application -Potential Costs -Recommendation Narrative -Strength Rationale -Link to Supporting Evidence -References

Rating	Definition
Strong	 benefits clearly exceed the harms (or harms clearly exceed the benefits for a negative recommendation) the quality of the supporting evidence is excellent/good (grade I or II)
Fair	 benefits exceed the harms (or harms clearly exceed the benefits for a negative recommendation) quality of evidence is not as strong (grade II or III)
Weak	 quality of evidence that exists is suspect or that well-done studies (grade I, II, or III)[*] show little clear advantage to one approach versus another
Consensus	 Expert opinion (grade IV) supports the guideline recommendation
Insufficient Evidence	 both a lack of pertinent evidence (grade V)[*] and/or an unclear balance between benefits and harms



Risks/Harms of Implementing This Recommendation

- Use caution in fluid-restricted patients receiving supplemental IV glutamine outside the primary PN solution. A commercially available IV glutamine solution with a concentration of 2.5% is currently available; therefore an increased volume of fluid is required to provide effective dosing (McClave et al, 2009; Vanek et al, 2011).
- Use caution in patients who are at risk for hyperammonemia (hepatic dysfunction) or azotemia (renal dysfunction) (Sacks, 2003; and Vanek et al, 2011).

Conditions of Application

- Availability and access to supplemental IV glutamine
- Ability to tolerate increased volume of fluid with supplemental IV glutamine.

Potential Costs Associated with Application

▶ Additional cost of supplemental enteral and IV glutamine.



	Recommendation Narrative:	
Impact on Infectious Complications in Critically III Adult Patients	-brief summary of the evidence	
EN: Six studies show that the balance of the evidence does not support use of supplemental ent infectious complications in adult critically ill patients	outcomes	
Evidence is based on the following studies: Conejero et al, 2002; Hall et al, 2003; Houdjik al, 2007; Schulman et al, 2006; and Spindler-Vesel et al, 2007	total, rooo, namarot	
IV: Six studies provide evidence that GLN-supplemented PN reduced infectious complications in patients in four of five positive quality RCTs	adult critically ill	
Evidence is based on the following studies: Déchelotte et al, 2006; Estívariz et al, 2008; Fu 2004; Fuentes-Orozco et al, 2008; Griffiths et al, 2002; and Yang and Xu, 2007.	uentes-Orozco et al,	
Impact on ICU LOS and Hospital LOS in Critically III Adult Patients		
EN: Three studies show that the evidence does not support the use of supplemental enteral GLN critically ill patients	•••••••••••••	
Evidence is based on the following studies: Conejero et al, 2002; Hall et al, 2003; and Hol	udjik et al, 1998	
IV: Nine studies provide evidence that GLN-supplemented PN does not reduce either ICU or hosp critically ill patients. Nine of 10 RCTs reported no difference in either hospital or ICU LOS with GL		
Evidence is based on the following studies: Cai et al, 2008; Déchelotte et al, 2006; Estívar Orozco et al, 2004; Fuentes-Orozco et al, 2008; Goeters et al, 2002; Powell-Tuck et al, 199 2007; and Ziegler et al, 2005.		
Impact on Mechanical Ventilation Days in Critically III Adult Patients		
EN: Three studies show that the evidence does not support the use of supplemental enteral gluta on mechanical ventilation in <u>adult critically ill</u> patients	amine to reduce days	
Evidence is based on the following studies: Conejero et al, 2002; Houdjik et al, 1998; and 2007	Spindler-Vesel et al,	
IV: Five studies provide evidence that IV GLN is unlikely to reduce days on mechanical ventilation patients. Four of five RCTs reported no difference in mechanical ventilation days with GLN added	-	



Strength Rationale -grade of supporting conclusions Minority Opinion –listed as needed

Recommendation Strength Rationale

- Subjects were critically ill, trauma patients. Studies for IV glutamine were of primarily middle-aged and predominantly male subjects.
- Grade I evidence is available for the conclusion statements regarding the impact of supplemental IV glutamine in adult critically ill patients on infectious complications and ICU LOS and hospital LOS
- Grade II evidence is available for the conclusion statement regarding the impact of supplemental IV glutamine in critically ill adult patients on mechanical ventilation days
- Grade II evidence is available for conclusion statements regarding the impact of supplemental enteral glutamine in adult critically ill patients on:

Mortality

- Infectious complications
- ICU LOS and hospital LOS
- Mechanical ventilation days
- Grade V evidence is available for the conclusion statement regarding the impact of supplemental IV glutamine on mortality and cost of care in adult critically ill patients.

Minority Opinions

None.



Supporting Evidence

Link back to conclusion statements, evidence summaries, The recommendations were created from the evidence analysi the blue hyperlinks below (recommendations rated consensus worksheets

In adult patients who are critically ill, does supplemental enteral glutamine impact mortality?

In adult patients who are critically ill, does supplemental enteral glutamine impact infectious complications?

In adult patients who are critically ill, does supplemental enteral glutamine impact ICU length of stay (LOS) and hospital LOS?

In adult patients who are critically ill, does supplemental enteral glutamine impact ventilator days?

In adult patients who are critically ill, does supplemental enteral glutamine impact cost of care?

In adult patients who are critically ill, does intravenous (IV) glutamine impact mortality?

In adult patients who are critically ill, does intravenous (IV) glutamine impact infectious complications?

In adult patients who are critically ill, does intravenous (IV) glutamine impact intensive care unitl (ICU) and hospital length of stay (LOS)?

In adult patients who are critically ill, does intravenous (IV) glutamine impact ventilator days?

In adult patients who are critically ill, does intravenous (IV) glutamine impact cost of care?

References

Conejero R, Bonet A, Grau T, Esteban A, Mesejo A, Montejo JC, López J, Acosta JA. Effect of a glutamine-enriched enteral diet on intestinal permeability and infectious morbidity at 28 days in critically-ill patients with systemic inflammatory response syndrome: A randomized, single-blind, prospective, multi-center study, Nutrition, 2002 Sep; 18 (9); 716-721.

Hall JC, Dobb G, Hall J, de Sousa R, Brennan L, McCauley R. A prospective randomized trial of enteral glutamine in critical

ferences	References:
Conejero R, Bonet A, Grau T, Esteban A, Mesejo A, Montejo JC, López J, Acosta JA. Effect of a glutamine-e	-link to
on intestinal permeability and infectious morbidity at 28 days in critically-ill patients with systemic inflamma syndrome: A randomized, single-blind, prospective, multi-center study. Nutrition. 2002 Sep; 18 (9): 716-72	worksheets
Hall JC, Dobb G, Hall J, de Sousa R, Brennan L, McCauley R. A prospective randomized trial of enteral glui	OR
illness. Intensive Care Med. 2003 Oct; 29(10): 1,710-1,716.	-link to external
Houdijk AP, Rijnsburger ER, Jansen J, Wesdorp RI, Weiss JK, McCamish MA, Teerlink T, Meuwissen SG, LG, van Leeuwen PA. Randomised trial of glutamine-enriched enteral nutrition on infectious morbidity in p	
trauma. Lancet. 1998 Sep 5; 352(9,130): 772-776.	use a systematic
Kumar S, Kumar R, Sharma SB, Jain BK. Effect of oral glutamine administration on oxidative stress, morbi critically ill surgical patients. Indian J Gastroenterol. 2007 Mar-Apr; 26(2): 70-73.	process

Schulman AS, Willoutts KF, Claridge JA, O'Donnell KB, Radigan AE, Evans HL, McElearney ST, Hedrick TL, Lowson SM, Schirmer BD, Young JS, Sawyer RG. Does enteral glutamine supplementation decrease infectious morbidity? Surg Infect. 2006 Feb; 7(1): 29-35.


Spindler-Vesel A, Bengmark S, Vovk I, Cerovic O, Kompan L. Synbiotics, prebiotics, glutamine or peptide in early enteral nutrition: A randomized study in trauma patients. *J Parenter Enteral Nutr.* 2007 Mar-Apr; 31 (2): 119-126.

Cai G, Yan J, Zhang Z, Yu Y. Immunomodulatory effects of glutamine enriched nutritional support in elderly patients with severe sepsis: A prospective, randomized, controlled study. *J Organ Dysfunction*. 2008, 4: 31-37.

Déchelotte P, Hasselmann M, Cynober L, Allaouchiche B, Coëffier M, Hecketsweiler B, Merle V, Mazerolles M, Samba D, Guillou YM, Petit J, Mansoor O, Colas G,Cohendy R, Barnoud D, Czernichow P, Bleichner G. L-alanyl-L-glutamine dipeptidesupplemented total parenteral nutrition reduces infectious complications and glucose intolerance in critically ill patients: The French controlled, randomized, double-blind, multicenter study. *Crit Care Med.* 2006 Mar; 34(3): 598-604.


Estívariz CF, Griffith DP, Luo M, Szeszycki EE, Bazargan N, Dave N, Daignault NM,Bergman GF, McNally T, Battey CH, Furr CE, Hao L, Ramsay JG, Accardi CR, CotsonisGA, Jones DP, Galloway JR, Ziegler TR. Efficacy of parenteral nutrition supplemented

Guideline Algorithms




Guideline Algorithms

right. Academy of Nutrition and Dietetics



Toolkit Development





Toolkit Development



Develop toolkits to apply guidelines

Conduct 60-day usability test of toolkit and revise

EBPC Review and Approval

Make toolkits available for purchase

Features of Evidence-Based Toolkits



Set of companion documents for application of the practice guideline

- Disease/condition specific
- Include:
 - MNT protocol for treatment of disease/condition
 - Documentation forms (progress notes, summary notes)
 - Outcomes monitoring sheets
 - Client education resources
 - Case studies
- Electronic downloadable purchase item





Objectives of Toolkits

To assist RD in:

- Implementing evidence-based practice
- Implementing NCP/SL
- Promoting consistency
- Promoting quality care
- Achievement of expected outcomes





A means to apply the NCP in a standard way using common language.

- Nutrition Assessment
- Nutrition Diagnosis
- Nutrition Intervention
- Monitoring and Evaluation

International Dietetics & Nutrition Terminology (IDNT) Reference Manual

Standardized Language for the Nutrition Care Process


AcademyofNutrition

FOURTH EDITION


Evidence-Based Practice Toolkits

right. Academy of Nutrition and Dietetics

 Disorders of Lipid Metabolism •Adult Weight Management Oncology •Critical Illness •Celiac Disease •Heart Failure •Diabetes Pediatric Weight Management

















Utilize Academy Evidence-based Practice Resources

- Evidence-based Toolkits application tools
- Educator modules- teaching tools for students
- EAL project presentations
- Academy Position Papers
- Journal of Academy of Nutrition and Dietetics – look for the EAL icon and journal website of EALrelated articles



right. Academy of

Utilize Academy Evidence-based Practice Resources




- One-week trial subscription or non-members = \$28 for nonmembers
- •NutriGuides App- NEW!!

•Provides 300+ recommendations

- •Categorized by:
 - -Disease/condition
 - •Topic

Nutrition Care Process

•Able to see the strength of the recommendation



EAL Subscriptions

EAL Subscription: Annual Individual EAL Subscription

Individual Subscription for non-ADA members:



<u>Click here</u> to view a brief powerpoint presentation (updated January 2012) that illustrates how much *more content* an Academy member or EAL subscriber can view on the Evidence Analysis Library. Academy members do not need to subscribe because access is free with an Academy membership. Email <u>store@adaevidencelibrary.com</u> if you have any questions.



Group Subscription Rates: If your association, institution, or organization wishes to purchase a subscription to the Academy of Nutrition and Dietetics Evidence Analysis Library®: contact Kay Howarter at <u>khowarter@eatright.org</u> for rates.

Individual Annual Subscription

Price: \$400.00 Member Price: \$0.00



EAL Subscription: One Week Trial Subscription to EAL

Trial Subscription with complete access to all of the content in the EAL for one week (7 days).



Click here to view a brief powerpoint presentation (updated January 2012) that illustrates how much more content an EAL subscriber can view on the Evidence Analysis Library.

Academy members receive access to the $\mathsf{EAL}^{\circledast}$ as a member benefit and cannot purchase a subscription.

Price: \$28.00 Member Price: \$0.00



right. Academy of Nutrition and Dietetics

-Utilize other evidence-based practice resources (e.g. guidelines.gov, Cochrane reports, Guidelines International Network, evidence-based guidelines from other organizations)

-Align with other medical fields basing their practice on evidence

-Make suggestions to <u>topics@adaevidencelibrary.com</u> or proposal to evidence-based practice committee







Department of Health and Human Services • National Institutes of Health National **Heart Lung and Blood** Institute People Science Health







Questions? eal@andevidencelibrary.com